Literature DB >> 15966931

Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis.

Alev Arat-Ozkan1, Ayşem Kaya, Zerrin Yigit, Huriye Balci, Bariş Okçün, Nuran Yazicioglu, Serdar Küçükoglu.   

Abstract

This study is designed to evaluate the N-terminal pro-BNP (NTproBNP) levels in patients with mitral stenosis (MS) and its possible correlation with clinical and echocardiographic parameters of the disease. The study group consisted of 29 patients with isolated MS (patients with greater mild regurgitation were excluded) and 20 normal control subjects of similar age and gender distribution. Blood samples for NTproBNP were collected at the time of clinical and echocardiographic examination. NTproBNP levels were elevated in patients with MS compared to controls (325 +/- 249 pg/dL [19.9-890] versus 43 +/- 36 pg/dL [5.76-193.3], P < 0.001). Patients with atrial fibrillation had significantly higher NTproBNP levels compared to those with sinus rhythm (561 +/- 281 pg/dL versus 254 +/- 194 pg/dL, P = 0.044). MS patients with sinus rhythm also had higher NTproBNP levels compared to controls (254 +/- 194 pg/dL versus 43 +/- 36 pg/dL, P = 0.00011). NT pro BNP levels correlated to the LA (R = 0.73, P < 0.0001) and RV (R = 0.41, P = 0.042) diameters, mitral valve area (R =-0.45, P = 0.025), mean mitral gradient (R = 0.57, P = 0.003), peak PAP (R = 0.7, P = 0.03), and NYHA functional class (R = 0.61, P = 0.007). In conclusion, serum NTproBNP levels correlate well with echocardiographic findings and functional class in patients with MS and can be used as a marker of disease severity. Additionally, it may have a potential use as an additional noninvasive and relatively cheap method in monitoring disease progression especially in patients with poor echocardiographic windows.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15966931     DOI: 10.1111/j.1540-8175.2005.04085.x

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  13 in total

1.  The relationship between the level of plasma B-type natriuretic peptide and mitral stenosis.

Authors:  Namik Kemal Eryol; Ali Dogan; Ibrahim Ozdogru; Mehmet Tugrul Inanc; Mehmet Gungor Kaya; Nihat Kalay
Journal:  Int J Cardiovasc Imaging       Date:  2006-12-21       Impact factor: 2.357

2.  Factors associated with the development of atrial fibrillation in patients with rheumatic mitral stenosis.

Authors:  Mehmet Ozaydin; Yasin Turker; Ercan Varol; Sule Alaca; Dogan Erdogan; Nigar Yilmaz; Abdullah Dogan
Journal:  Int J Cardiovasc Imaging       Date:  2010-03-24       Impact factor: 2.357

Review 3.  Interpretation and use of natriuretic peptides in non-congestive heart failure settings.

Authors:  Shih-Hung Tsai; Yen-Yue Lin; Shi-Jye Chu; Ching-Wang Hsu; Shu-Meng Cheng
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

4.  Plasma brain natriuretic peptide concentrations in patients with valvular heart disease.

Authors:  Vishal Sharma; Ralph A Stewart; Mildred Lee; Ruvin Gabriel; Niels Van Pelt; David E Newby; Andrew J Kerr
Journal:  Open Heart       Date:  2016-05-04

5.  N-terminal-pro-brain natriuretic peptide, a surrogate biomarker of combined clinical and hemodynamic outcomes following percutaneous transvenous mitral commissurotomy.

Authors:  K P Ranganayakulu; D Rajasekhar; V Vanajakshamma; C Santosh Kumar; P Vasudeva Chetty
Journal:  J Saudi Heart Assoc       Date:  2015-07-18

6.  The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology.

Authors:  Van Kimmenade
Journal:  Biomark Insights       Date:  2007-02-07

7.  Brain natriuretic peptide in pregnant women with heart disease.

Authors:  Karanvir Singh; Pooja Sikka; Vanita Suri; Rishikesh Prasad; Madhu Khullar; Rajesh Vijayvergiya
Journal:  Obstet Med       Date:  2019-02-02

8.  Ratio of preoperative atrial natriuretic peptide to brain natriuretic peptide predicts the outcome of the maze procedure in mitral valve disease.

Authors:  Masafumi Sato; Akihito Mikamo; Hiroshi Kurazumi; Ryo Suzuki; Masanori Murakami; Toshiro Kobayashi; Koich Yoshimura; Kimikazu Hamano
Journal:  J Cardiothorac Surg       Date:  2013-02-28       Impact factor: 1.637

Review 9.  Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions.

Authors:  Michael A Burke; William G Cotts
Journal:  Heart Fail Rev       Date:  2007-03-08       Impact factor: 4.654

Review 10.  Clinical Applications of Natriuretic Peptides in Assessment of Valvular Heart Disease.

Authors:  Abhishek Sharma; Vaseem Ahmed; Aakash Garg; Chirag Aggarwal
Journal:  Dis Markers       Date:  2015-07-22       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.